Dec 8 (Reuters) - The U.S. Food and Drug Administration on Wednesday authorized the use of AstraZeneca's (AZN.L) antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.